Discordant Nadir GH After Oral Glucose and IGF-I Levels on Treated Acromegaly: Refining the Biochemical Markers of Mild Disease Activity


Autoria(s): ELIAS, P. C. L.; LUGAO, H. B.; PEREIRA, M. C.; MACHADO, H. R.; CASTRO, M. de; MOREIRA, A. C.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

19/10/2012

19/10/2012

2010

Resumo

Biochemical markers for remission on acromegaly activity are controversial. We studied a subset of treated acromegalic patients with discordant nadir GH levels after oral glucose tolerance test (oGTT) and IGF-I values to refine the current consensus on acromegaly remission. We also compared GH results by two GH immunoassays. From a cohort of 75 treated acromegalic patients, we studied 13 patients who presented an elevated IGF-I despite post-oGTT nadir GH of <= 1 mu g/l. The 12-h daytime GH profile (GH-12 h), nadir GH after oGTT, and basal IGF-I levels were studied in patients and controls. Bland-Altman method showed high concordance between GH assays. Acromegalic patients showed higher mean GH-12 h values (0.71+/-0.36 vs. 0.31+/-0.28 mu g/l; p<0.05) and nadir GH after oGTT (0.48+/-0.32 vs. 0.097+/-0.002 mu g/l; p<0.05) as compared to controls. Nadir GH correlated with mean GH-12 h (r=0.92, p<0.05). The mean GH-12 h value from upper 95% CI of controls (0.54 mu g/l) would correspond to a theoretical normal nadir GH of <= 0.27 mu g/l. Patients with GH nadir <= 0.3 mu g/l had IGF-I between 100-130% ULNR (percentage of upper limit of normal range) and mean GH-12 h of 0.35+/-0.15, and patients with GH nadir >0.3 and <= 1 mu g/l had IGF-I >130% ULNR and mean GH-12 h of 0.93+/-0.24 mu g/l. Our data integrate daytime GH secretion, nadir GH after oGTT, and plasma IGF-I concentrations showing a continuum of mild residual activity in a subgroup of treated acromegaly with nadir GH values <= 1 mu g/l. The degree of increased IGF-I levels and nadir GH after oGTT are correlated with the subtle abnormalities of daytime GH secretion.

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)[06/56716-0]

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)[07/58365-3]

Conselho Nacional de Desenvolvimento Cientfico e Tecnologico (CNPq)[304532/2006-1]

Identificador

HORMONE AND METABOLIC RESEARCH, v.42, n.1, p.50-55, 2010

0018-5043

http://producao.usp.br/handle/BDPI/24163

10.1055/s-0029-1239522

http://dx.doi.org/10.1055/s-0029-1239522

Idioma(s)

eng

Publicador

GEORG THIEME VERLAG KG

Relação

Hormone and Metabolic Research

Direitos

restrictedAccess

Copyright GEORG THIEME VERLAG KG

Palavras-Chave #acromegaly #GH #IGF-I #GROWTH-HORMONE-SECRETION #POSTOPERATIVE-PATIENTS #CONSENSUS STATEMENT #TOLERANCE TEST #FOLLOW-UP #ASSAY #MANAGEMENT #REMISSION #GUIDELINES #MORTALITY #Endocrinology & Metabolism
Tipo

article

original article

publishedVersion